Literature DB >> 30201369

Dyslipidemias in clinical practice.

Manuel Castro Cabezas1, Benjamin Burggraaf1, Boudewijn Klop2.   

Abstract

Most dyslipidemic conditions have been linked to an increased risk of cardiovascular disease. Over the past few years major advances have been made regarding the genetic and metabolic basis of dyslipidemias. Detailed characterization of the genetic basis of familial lipid disorders and knowledge concerning the effects of environmental factors on the expression of dyslipidemias have increased substantially, contributing to a better diagnosis in individual patients. In addition to these developments, therapeutic options to lower cholesterol levels in clinical practice have expanded even further in patients with familial hypercholesterolemia and in subjects with cardiovascular disease. Finally, promising upcoming therapeutic lipid lowering strategies will be reviewed. All these advances will be discussed in relation to current clinical practice with special focus on common lipid disorders including familial dyslipidemias.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lipoprotein; hypercholesterolemia; hyperlipidemia; lipid disorder; treatment

Mesh:

Substances:

Year:  2018        PMID: 30201369     DOI: 10.1016/j.cca.2018.09.010

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Impact of Alexithymia on the Lipid Profile in Major Depressed Individuals.

Authors:  Camille Point; Benjamin Wacquier; Marjorie Dosogne; Mohammed Al Faker; Hadrien Willame; Gwenolé Loas; Matthieu Hein
Journal:  J Lipids       Date:  2022-06-16

2.  The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism.

Authors:  Shengjie Tang; Fang Wu; Xihua Lin; Weiwei Gui; Fenping Zheng; Hong Li
Journal:  J Diabetes Res       Date:  2020-05-04       Impact factor: 4.011

3.  Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis.

Authors:  Chuannan Zhai; Kai Hou; Rui Li; YueCheng Hu; JingXia Zhang; YingYi Zhang; Le Wang; Rui Zhang; HongLiang Cong
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

4.  A Comorbidity Model of Myocardial Ischemia/Reperfusion Injury and Hypercholesterolemia in Rat Cardiac Myocyte Cultures.

Authors:  András Makkos; Ágnes Szántai; János Pálóczi; Judit Pipis; Bernadett Kiss; Paola Poggi; Péter Ferdinandy; Alexandros Chatgilialoglu; Anikó Görbe
Journal:  Front Physiol       Date:  2020-01-09       Impact factor: 4.566

5.  Diet and Nutraceutical Supplementation in Dyslipidemic Patients: First Results of an Italian Single Center Real-World Retrospective Analysis.

Authors:  Andrea Pasta; Elena Formisano; Anna Laura Cremonini; Elio Maganza; Erika Parodi; Sabrina Piras; Livia Pisciotta
Journal:  Nutrients       Date:  2020-07-10       Impact factor: 5.717

6.  Ontogeny of circulating lipid metabolism in pregnancy and early childhood - a longitudinal population study.

Authors:  Satvika Burugupalli; Adam Alexander T Smith; Gavriel Oshlensky; Kevin Huynh; Corey Giles; Tingting Wang; Alexandra George; Sudip Paul; Anh Nguyen; Thy Duong; Natalie Mellett; Michelle Cinel; Sartaj Ahmad Mir; Li Chen; Markus R Wenk; Neerja Karnani; Fiona Collier; Richard Saffery; Peter Vuillermin; Anne-Louise Ponsonby; David Burgner; Peter Meikle
Journal:  Elife       Date:  2022-03-02       Impact factor: 8.140

7.  Early myocardial functional abnormalities in primary dyslipidemia: clinical and echocardiographic observations in young children from a highly consanguineous population.

Authors:  Nehal M El-Koofy; Aya M Fattouh; Areef Ramadan; Mohamed A Elmonem; Dina H Hamed
Journal:  Clin Exp Pediatr       Date:  2021-12-08

8.  Correlation Between the APOB rs1042034 SNP and Blood Lipid Characteristics of 2 Ethnic Groups in China.

Authors:  Fen-Han Zhang; Rui-Xing Yin; Li-Mei Yao; Rong-Qin Yan; Li Lu; Yuan Su
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.